ABSK061 not checked

Abbisko Therapeutics Co, Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there…”In the company’s words, NCT06632262 on ClinicalTrials.gov
Tested for
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors, Achondroplasia
Main trialPhase 2
“The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations”In the company’s words, NCT06632262 on ClinicalTrials.gov

Other drugs for Urothelial Carcinoma

All 83 drugs for Urothelial Carcinoma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Nov 2029 A Phase 2 Clinical Study of ABSK061 and ABSK043
Phase 1/2Not yet recruiting 15 Dec 2028 A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
Phase 1Unknown 30 Apr 2025 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Phase 1Completed 30 Jul 2025 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ABSK061

Following is part of Solo: you see every change to ABSK061 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in